Printer Friendly

HEALTHWATCH INTRODUCES NEW LIFE SCIENCES MVL CLASSIC

 HEALTHWATCH INTRODUCES NEW LIFE SCIENCES MVL CLASSIC
 BROOMFIELD, Colo., March 11 /PRNewswire/ -- Life Sciences, a


division of HealthWatch Inc. (NASDAQ: HEAL), today announced the introduction of its new "MVL Classic," a noninvasive diagnostic testing system for the detection of peripheral vascular disease.
 The Classic's design evolved from HealthWatch's flagship vascular testing system, the MVL Modulab(R). It provides physicians with many of the features of the MVL Modulab(R), including the Life Sciences' PVR(R) technology, the most widely used physiologic test in hospitals and vascular laboratories. The new Classic sells for approximately 40 percent less than the MVL Modulab(R).
 The Classic is a key component in HealthWatch's strategy to redesign its products, allowing lower prices while maintaining strong profit margins. This strategy coincides with the establishment of HealthWatch's new sales force whose target will be physician offices and clinics.
 Aimed at expanding HealthWatch's market share in the growing vascular testing market, the Classic offers more testing capabilities than any other product in its price range. The totally modular design allows the user to choose from a full range of clinical testing modalities allowing the Classic to be upgraded by purchasing additional equipment from HealthWatch.
 "The Classic meets the goals of having a full range of products available for the vascular marketplace," says Charles P. Spickert, president/COO of HealthWatch. "Initial response both domestically and internationally is very positive. The Classic's combination of expanded testing capabilities and low price put it significantly ahead of any comparable competitive system. We will also be introducing new cardiology products later this year."
 Based in Broomfield, HealthWatch is a leading manufacturer of medical equipment for the purpose of diagnosing human cardiovascular disease. HealthWatch markets cardiology and vascular products under its Cambridge Medical and Life Sciences labels, respectively.
 -0- 3/11/92
 /CONTACT: Sanford L. Schwartz of HealthWatch, 303-465-2000/
 (HEAL) CO: HealthWatch Inc.; Life Sciences ST: Colorado IN: HEA SU:


BB -- DV001 -- 7186 03/11/92 09:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1992
Words:325
Previous Article:VIETNAM VETERANS OF AMERICA CREATES 'ARTICLE 99 AWARDS' TO HONOR INDIVIDUALS WHO BATTLE THE VA
Next Article:JOHN HESTER NAMED SENIOR VICE PRESIDENT, LEGAL AFFAIRS AND CORPORATE OPERATIONS OF ORION PICTURES CORPORATION
Topics:


Related Articles
HEALTHWATCH BUILDS PHYSICIAN OFFICE MARKET SALES FORCE
HEALTHWATCH ANNOUNCES NEW SPIROMETRY PRODUCT LINE
HEALTHWATCH INTRODUCES NEW VASCULAR TESTING EQUIPMENT - PAP II
HEALTHWATCH RECEIVES FDA APPROVAL TO MARKET NEW PC-BASED EXERCISE STRESS TESTING SYSTEM
HEALTHWATCH RECEIVES GOLD AESCULAPIUS AWARD IN POLAND
HEALTHWATCH ANNOUNCES NEW HOLTER MONITOR PRODUCT LINE
HEALTHWATCH REPORTS THIRD QUARTER RESULTS
HEALTHWATCH ANNOUNCES PLANNED ACQUISITION OF METAMED INC.
HEALTHWATCH ANNOUNCES FUNDING AGREEMENT WITH THE ROCKIES FUND
HEALTHWATCH REPORTS 1993 OPERATING RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters